Why the study?
Do ranolazine and its metabolites improve ECG parameters and cardiac indices in mice with isoprenaline-induced myocardial ischemia?
Do ranolazine and its metabolites improve ECG parameters and cardiac indices in mice with isoprenaline-induced myocardial ischemia?
The ranolazine metabolites CVT-2738 and CVT-2513 exhibit moderate anti-myocardial ischemia activity in mice, though they are less potent than the parent drug ranolazine.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in isoprenaline mouse ischemia; leaves open whether CVT-2738 metabolites warrant human translation versus ranolazine.
The anti-anginal drug Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, is thought to modulate the metabolism during myocardial ischemia by activating pyruvate dehydrogenase activity to promote glucose oxidation. Ranolazine and its five principal metabolites: CVT-2512, CVT-2513, CVT-2514, CVT-2738 and CVT-4786, were synthesized. The effect of Ranolazine and its metabolites on the ECG (electrocardiogram) of mice with myocardial ischemia induced by isoprenaline and their effect on alleviating the symptom of myocardial ischemia were tested and compared. The results showed that CVT-2738 and CVT-2513 could be protective against mice myocardial ischemia induced by isoprenaline. Within all the metabolites tested in this study, CVT-2738 exhibited the best potency, however, it was still less potent than Ranolazine.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: